DFMO maintenance for relapsed Ewing sarcoma or osteosarcoma
Treatments studied
Part of Cancer clinical trials.
This trial tests a drug called DFMO given as maintenance therapy to keep cancer from coming back. It is for people under 40 who have finished treatment for relapsed Ewing sarcoma or osteosarcoma and currently show no signs of cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are under 40 years old
- You have relapsed Ewing sarcoma or osteosarcoma and have completed all planned treatment with no evidence of cancer left
- You are up and around most of the day (ECOG score 0, 1, or 2)
- Enough time has passed since your last chemotherapy (2 weeks), antibody therapy (3 weeks), or radiation (2 weeks to 3 months depending on type)
- Your blood counts, kidney function, and liver function are within acceptable levels
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial combines four targeted drugs (gefitinib, trametinib, disulfiram, sunitinib) with standard chemotherapy to treat osteosarcoma that has spread or come back. The goal is to see if this drug mix helps shrink tumors or keep them from growing.
This trial tests a drug called eflornithine (DFMO) for people with Ewing sarcoma or osteosarcoma that has come back or spread. The goal is to see if DFMO can help control the cancer after standard treatment.
This Phase 2 study tests DFMO (a maintenance medicine) to help stop medulloblastoma from coming back or worsening after prior treatment. It focuses on children and young people with specific high-risk tumor types or tumors that have returned or not responded well to treatment.
This trial studies a drug called DFMO for children and young adults with certain rare cancers that have not responded to standard treatments or have come back. DFMO may help stop cancer cells from growing.
This trial tests a combination of three drugs (dinutuximab beta, irinotecan, and rapamycin) for people with bone cancers like osteosarcoma or Ewing sarcoma that have come back or not responded to treatment. The goal is to see if this combination can shrink or slow the tumors.
This trial tests a combination of two drugs (eflornithine and AMXT 1501) for children and young adults with certain types of cancer that have relapsed or not responded to standard treatment, or for a specific brain tumor (DIPG) at diagnosis. The goal is to see if this drug pair is safe and effective.
Hear when a new Osteosarcoma Recurrent trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.